Mirum Pharmaceuticals nabs $120 mln Series A in NEA-led round
Mirum Pharmaceuticals, a clinical-stage therapeutics company focused on treating cholestatic liver diseases, has secured $120 million in Series A financing. New Enterprise Associates led the round with participation from Deerfield Management, Frazier Healthcare Partners, Novo Holdings A/S, Pappas Capital, RiverVest Venture Partners and Rock Springs Capital.
7 November 2018•1 min read
